Healthcare Stocks Face Policy Split After Midterm
A divided Washington can matter less for the headline index than for the mix of healthcare subindustries inside an ETF. This article highlights that point well: drugmakers, managed-care firms and life-science tools companies do not respond to policy in the same way. For investors, the more useful lens is not simply “healthcare,” but which regulatory lever is being pulled and which business models are most exposed.
Index construction and concentration also matter. TMED’s top holdings include Eli Lilly and UnitedHealth, so the fund is not a broad equal-weighted basket of healthcare names. That means a relatively small number of large positions can shape outcomes, especially when policy news affects pricing power, Medicaid reimbursement or research funding. In sector ETFs, concentration can amplify both the upside and the downside of a policy shift.
There are a few practical portfolio points here. First, an actively managed ETF like TMED may adjust more nimbly than a passive benchmark, but investors still need to watch fees, liquidity and tracking behavior relative to the strategy’s stated goal. Second, healthcare policy changes often arrive in stages, so rebalancing matters more than reacting to one election result. Finally, the article is a reminder that healthcare is not just a defensive sleeve; it also carries valuation, reimbursement and regulatory risk that can persist even when broader market sentiment looks calm.
Key Takeaways:
- Democrats will hold majorities in both the House and Senate, creating a divided government in Washington.
- Eli Lilly and UnitedHealth lead TMED’s holdings, giving the fund exposure to both drugmakers and insurers.
- Life science tools makers could gain from higher NIH funding, depending on how the money is spent.
See more: Fed Hiking Cycle May Run Longer Than Markets Expect
Instead, more meaningful implications could emerge at the sector level, Murray wrote. In healthcare, Democratic efforts on Medicaid could help hospitals and insurers, while drug prices could draw bipartisan attention. Gil Fortgang, an associate analyst covering Washington and regulatory research at T. Rowe Price, expects Democrats to prioritize moderating some planned Medicaid cuts. Success could help hospitals and health insurers exposed to the program. Lowering drug prices could also become a bipartisan issue in talks over the debt ceiling, or the cap on federal borrowing, Fortgang wrote. However, the Trump administration appears to prefer making deals with companies over legislated price controls.Midterm Policy Themes Inside a Healthcare ETF
Both groups sit near the top of the T. Rowe Price Health Care ETF (TMED). Eli Lilly and Co. (LLY) was the actively managed fund’s largest holding at 6.15% as of Nov. 4, according to T. Rowe Price. Health insurer UnitedHealth Group Inc. (UNH) followed at 5.16%. Life science tools makers also rank among its top 10 holdings, the firm’s data show. Thermo Fisher Scientific Inc. (TMO) makes up 3.4% of the fund, while Agilent Technologies Inc. (A) accounts for 3.01%. A divided government could also boost the budget for the National Institutes of Health, which funds medical research, Fortgang wrote. Still, whether tools companies benefit depends on how that money is spent. TMED launched in June 2025 and had $34.5 million in net assets as of Nov. 3, according to T. Rowe Price. Its expense ratio is 0.44%. The ETF returned 27.7% over the year through Sept. 30, the firm reported. Its benchmark, the S&P Health Care Select Sector Index, gained 23.02%. The debt ceiling talks Fortgang flagged may still be a while off. The $41.1 trillion limit is expected to be reached around mid-2027, wrote Blerina Uruçi, T. Rowe Price’s chief U.S. economist. The Treasury could then run out of cash and turn to emergency accounting measures in late 2027 or early 2028.Enjoyed this article? Sign up for our newsletter to receive regular insights and stay connected.